U
IDXG

UBS’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

UBS’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$6K Buy
24
+5
+26% +$1.67K ﹤0.01% 9341
2014
Q2 		$8K Buy
19
+17
+850% +$7.84K ﹤0.01% 9137
2014
Q1 		$1K Buy
+2
New +$1.04K ﹤0.01% 10258
2013
Q3 		– Sell
-75
Closed -$35K – 10863
2013
Q2 		$35K Buy
+75
New +$34K ﹤0.01% 7197

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

UBS's IDXG Position: Q3 2014 in Review

UBS increased its Interpace Biosciences, Inc. Common Stock (IDXG) stake by 26% in Q3 2014, buying an estimated $1.67K and bringing the position to 24 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9341.

UBS first reported a position in IDXG in Q2 2013 and has held it in 4 quarters since. The position peaked at $35K in Q2 2013. 27 funds tracked by Wall St. Rank hold IDXG as of Q3 2014.

  • UBS held 24 shares of Interpace Biosciences, Inc. Common Stock worth $6K as of Q3 2014.
  • UBS bought 5 Interpace Biosciences, Inc. Common Stock shares in Q3 2014, an estimated $1.67K.
  • Interpace Biosciences, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9341 holding.
  • UBS first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and has held it in 4 quarters since.
  • UBS's Interpace Biosciences, Inc. Common Stock position peaked at $35K in Q2 2013.
  • 27 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.